Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)
- 1 November 1995
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 76 (12), 899-905
- https://doi.org/10.1016/s0002-9149(99)80259-8
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Screening experience and baseline characteristics in the West of Scotland coronary prevention studyThe American Journal of Cardiology, 1995
- Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectorisThe American Journal of Cardiology, 1995
- Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimensThe American Journal of Cardiology, 1995
- Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levelsThe American Journal of Cardiology, 1995
- Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)The American Journal of Cardiology, 1995
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Pravastatin, lipids, and major coronary eventsThe American Journal of Cardiology, 1994
- Cholesterol and total mortality: need for larger trials.BMJ, 1992
- Clinical Implications of New Drugs for Lowering Plasma Cholesterol ConcentrationsDrugs, 1991
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987